The overarching theme of this Tobacco Center of Regulatory Science is the development of improved models to inform tobacco product regulatory strategies that integrate 1) economic impacts of tobacco use on health costs, 2) risk perceptions, perceived acceptability, consumer responses to pro-tobacco marketing and anti-tobacco messages and other social determinants of tobacco use, and 3) rapid changes in risk due to tobacco use and secondhand smoke exposure as manifested in cardiovascular and pulmonary dysfunction. This TCORS includes five full projects (one on economic models, two on behavioral models, and two on cardiovascular and pulmonary disease models), two developmental projects (one on behavioral models and one on cardiovascular and pulmonary disease models), three Cores (Administrative, Informatics and Analysis, and Biomarker), a postdoctoral training program and a process for selecting future developmental projects. The results will inform FDA regulation of the manufacture, distribution and marketing of tobacco products by providing an improved scientific framework in which to evaluate the likely effects of specific regulatory strategies by developing 1) improved economic models for analysis of proposed regulations that account for short-term as well as long-term effects of tobacco use, 2) better understanding of behavioral and social determinants of tobacco use (including perception of risk and decision making processes) to inform the economic models, regulation of marketing, and public education about risks of tobacco products, and 3) functional biomarkers of acute cardiopulmonary responses to tobacco use and secondhand smoke that may predict future disease and also support development of improved economic models. In particular, these improved economic models will integrate the rapid changes in risk due to reductions in cardiovascular and pulmonary diseases which would be expected to result from FDA regulatory decisions. This TCORS is built on the UCSF Center for Tobacco Control Research and Education's tradition of strong transdisciplinary and collaborative research, education and service.
This TCORS will inform FDA regulation by developing new economic models that account for short-term and long-term effects of tobacco use, developing a better understanding of behavioral determinants of tobacco use, and identifying functional biomarkers of acute cardiopulmonary responses to tobacco use that could be used in premarket testing of tobacco products.
|Halpern-Felsher, Bonnie; Kim, Hyoshin (2018) Measuring E-cigarette use, dependence, and perceptions: Important principles and considerations to advance tobacco regulatory science. Addict Behav 79:201-202|
|Nabavizadeh, Pooneh; Liu, Jiangtao; Havel, Christopher M et al. (2018) Vascular endothelial function is impaired by aerosol from a single IQOS HeatStick to the same extent as by cigarette smoke. Tob Control 27:s13-s19|
|Kulik, Margarete C; Lisha, Nadra E; Glantz, Stanton A (2018) E-cigarettes Associated With Depressed Smoking Cessation: A Cross-sectional Study of 28 European Union Countries. Am J Prev Med 54:603-609|
|Glantz, Stanton A; Gardiner, Philip (2018) Local Movement to Ban Menthol Tobacco Products as a Result of Federal Inaction. JAMA Intern Med 178:711-713|
|Barrington-Trimis, Jessica L; Gibson, Laura A; Halpern-Felsher, Bonnie et al. (2018) Type of E-Cigarette Device Used Among Adolescents and Young Adults: Findings From a Pooled Analysis of Eight Studies of 2166 Vapers. Nicotine Tob Res 20:271-274|
|Glantz, Stanton A; Bareham, David W (2018) E-Cigarettes: Use, Effects on Smoking, Risks, and Policy Implications. Annu Rev Public Health 39:215-235|
|Yao, Tingting; Sung, Hai-Yen; Wang, Yingning et al. (2018) Healthcare costs attributable to secondhand smoke exposure at home for U.S. adults. Prev Med 108:41-46|
|McKelvey, Karma; Baiocchi, Mike; Ramamurthi, Divya et al. (2018) Youth say ads for flavored e-liquids are for them. Addict Behav :|
|Moazed, Farzad; Chun, Lauren; Matthay, Michael A et al. (2018) Assessment of industry data on pulmonary and immunosuppressive effects of IQOS. Tob Control 27:s20-s25|
|St Helen, Gideon; Jacob Iii, Peyton; Nardone, Natalie et al. (2018) IQOS: examination of Philip Morris International's claim of reduced exposure. Tob Control 27:s30-s36|
Showing the most recent 10 out of 101 publications